肿瘤预防与治疗2024，Vol.37Issue(5)：372-384,13.DOI:10.3969/j.issn.1674-0904.2024.05.003
《2024.V1版卵巢癌包括输卵管癌和原发性腹膜癌》NCCN证据块指南解读
Interpretation of the NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines)with NCCN Evidence Blocks™——Ovarian Cancer Including Fal-lopian Tube Cancer and Primary Peritoneal Cancer(2024 Version 1)
摘要
Abstract
Ovarian malignant tumor is one of the three major malignant tumors in gynecology.It has a low incidence rate but a high mortality rate,and the mortality rate is still in an increasing trend in the last 20 years.The course of ovarian canc-er is often manifested as frequent recurrence requiring multi-course chemotherapy.At present,National Comprehensive Cancer Network(NCCN)guidelines have recommended chemotherapy regimens for all stages of ovarian cancer,but how to choose different chemotherapy regimens recommended at the same level remains unclear.NCCN released Clinical Practice Guidelines in Oncology(NCCN Guidelines)with NCCN Evi-dence Blocks™ in 2015,which compares different chemothera-peutic regimens in five dimensions:E.efficacy of regimens/drugs;S.safety of regimens/drugs;Q.quality of evidence;C.consistency of evidence;and A.affordability of regimens/drugs,in order to choose more suitable chemotherapy regimens ac-cording to patients'different conditions and personal status,thus achieving individualized and precise treatment.关键词
卵巢癌/输卵管癌/原发性腹膜癌/证据块/指南解读Key words
Ovarian cancer/Fallopian tube cancer/Primary peritoneal cancer/Evidence blocks/Guideline interpretation分类
医药卫生引用本文复制引用
张鹏闯,胡丽娟,吴涛,胡媛,王国庆..《2024.V1版卵巢癌包括输卵管癌和原发性腹膜癌》NCCN证据块指南解读[J].肿瘤预防与治疗,2024,37(5):372-384,13.基金项目
This study was supported by grants from Science and Technology Department of Shaanxi Province(No.S2023-JC-QN-1665)and Beijing Science and Technology Innovation Medical Development Foundation(No.KC2021-JX-1086-134). 陕西省自然科学基础研究计划资助项目(编号:S2023-JC-QN-1665) （No.S2023-JC-QN-1665）
北京科创医学发展会齐鲁肿瘤疾病研究基金项目(编号:KC2021-JX-1086-134) （编号:KC2021-JX-1086-134）
